Study start-up is the operational phase of a clinical trial that runs from protocol finalization through the enrollment of the first participant. It covers everything a sponsor, CRO, and site must complete before a single subject can be screened: site selection, contract and budget negotiation, institutional review board (IRB) or ethics committee approval, collection of regulatory and essential documents, and the Site Initiation Visit (SIV) that formally activates the site. Start-up is widely cited as the single largest source of avoidable delay in clinical trial timelines, which is why sponsors, CROs, and sites treat it as a distinct phase to be planned, tracked, and benchmarked in its own right — not simply “the paperwork before the trial begins.”
Study start-up vs. the Site Initiation Visit
These two terms are often used loosely as if interchangeable, but they describe different things. The Site Initiation Visit is a single monitoring visit — the final readiness check that clears a site to begin enrolling once every start-up prerequisite is already in place. Study start-up is the entire multi-week-to-multi-month phase that leads up to that visit: identifying and qualifying the site, negotiating the clinical trial agreement and budget, obtaining IRB/ethics approval, and assembling the regulatory document package. The SIV is the last checkpoint of study start-up, not a synonym for it.
What the study start-up phase covers
Study start-up spans five broadly sequential (though often overlapping) workstreams:
- Site selection and feasibility. The sponsor or CRO identifies candidate sites, collects feasibility questionnaires, and evaluates each site against criteria such as prior enrollment performance, patient population access, investigator experience, and infrastructure. See CASRAI’s guides on Clinical Trial Site Selection and Clinical Trial Feasibility Assessment for how this evaluation is structured.
- Contract and budget negotiation. The sponsor and site (or the site’s institution) negotiate and execute the clinical trial agreement (CTA) and the per-subject/per-procedure budget. This is frequently the single slowest workstream in start-up, since it typically runs through institutional legal and finance offices with their own review cycles, independent of the clinical or regulatory tracks.
- IRB / ethics committee approval. The site (or a central/single IRB covering multiple sites) reviews and approves the protocol, informed consent form, and recruitment materials before any subject can be consented. See CASRAI’s guide on preparing a protocol for IRB submission and its dictionary entries on Informed Consent Form (ICF) and Central IRB / Single IRB (sIRB).
- Regulatory and essential document collection. The site assembles the pre-trial essential-document set specified in ICH E6(R2) Section 8 — investigator’s brochure acknowledgment, delegation-of-authority log, staff training and licensure records, financial disclosure forms, and (for FDA-regulated trials) a completed FDA Form 1572 where applicable — and files it into the site’s contribution to the Trial Master File (TMF).
- Site initiation and activation. Once the first four workstreams converge, the monitor conducts the Site Initiation Visit to confirm all prerequisites are simultaneously satisfied, and the site is formally activated to begin screening.
In practice these workstreams run partly in parallel — site selection and IRB submission often overlap, for example — but a site cannot be activated until all five have converged, which is what makes the slowest workstream the effective bottleneck for the whole phase.
How long study start-up typically takes
Study start-up timelines vary widely by trial phase, therapeutic area, number of sites, and country, but industry benchmarking research consistently identifies it as a major share of total trial timeline. Tufts Center for the Study of Drug Development (CSDD) benchmarking research, reported by Applied Clinical Trials, has found site selection and start-up activities can account for as much as 30% of total trial timelines, with the process from initial site identification through site initiation averaging roughly seven months, and with Phase I studies typically moving faster (roughly 6-7 months from pre-study visit to first patient in) than Phase II-IV studies (roughly 10 months on average). The same research found that most of the cycle time — and the greatest variability between sites — occurs in the earlier stages (from the pre-study/selection visit through contract execution), while the final stretch from contract execution to first patient in tends to be comparatively consistent across therapeutic area, site type, and region. These figures are industry benchmarks, not a regulatory standard or a guarantee for any individual trial; a program’s own historical cycle-time data is a more reliable planning input than any external benchmark.
Where study start-up gets stuck: common bottlenecks
- Contract and budget negotiation. Because the CTA and budget typically route through an institution’s separate legal and finance review chains, this workstream commonly takes longer, and varies more, than the clinical and regulatory workstreams running in parallel. Standardized contract templates and pre-negotiated master agreements between a sponsor/CRO and a site’s institution are the most common mitigation.
- IRB review cycles and resubmissions. An incomplete or unclear IRB application is frequently sent back for revision before it is even reviewed on the merits, adding a full review cycle. See CASRAI’s IRB Application guide for what a complete submission needs to include the first time.
- Document turnaround between sponsor and site. Sites are often waiting on the sponsor for finalized protocol versions, investigator’s brochure updates, or IRB-approved consent language before they can complete their own document package — a two-way dependency that stalls if either side is slow.
- Site overcommitment and mismatched selection. A site that was selected without a realistic feasibility assessment of its eligible patient population or staff capacity can pass every start-up milestone on paper and still fail to enroll once active — underscoring why the feasibility step earlier in start-up matters as much as speed later in the process.
- Sequential rather than parallel workflows. Programs that wait for IRB approval before beginning contract negotiation (rather than running both simultaneously once the protocol is stable) add the two timelines together instead of letting the longer one set the pace.
Who is responsible for study start-up
Study start-up is cross-functional by nature, and no single role owns every workstream:
- A Clinical Research Associate (CRA) or Clinical Trial Associate (CTA), typically employed by the sponsor or a CRO, coordinates the overall start-up timeline, tracks document status across sites, and conducts the SIV.
- Institutional contracts and grants/legal offices negotiate and execute the clinical trial agreement and budget on the site side.
- The site’s Human Research Protection Program (HRPP) or IRB office manages ethics review and approval.
- Clinical research coordinators at the site assemble the site regulatory binder and essential-document package.
- A sponsor’s clinical operations and site management functions track start-up milestones across the full portfolio of sites, since a single slow site can delay a trial’s overall enrollment start even when every other site is ready.
Because these functions sit in different organizations reporting to different timelines, study start-up is as much a coordination and project-management problem as a regulatory one — which is why sponsors increasingly track it with dedicated start-up milestones inside their clinical trial management systems (CTMS) rather than treating it as an informal handoff between functions.
Frequently asked questions
What is study start-up in clinical trials?
Study start-up is the phase of a clinical trial between protocol finalization and enrollment of the first participant, encompassing site selection, contract and budget negotiation, IRB/ethics approval, regulatory document collection, and the Site Initiation Visit that formally activates the site.
How long does study start-up usually take?
It varies by trial phase, number of sites, and country, but industry benchmarking research (Tufts CSDD, reported by Applied Clinical Trials) has found the process from site identification through site initiation averages roughly seven months, with the earliest stages — site selection through contract execution — typically taking the longest and varying the most between sites.
What’s the difference between study start-up and a Site Initiation Visit?
The Site Initiation Visit (SIV) is a single visit — the final readiness check before enrollment opens. Study start-up is the entire phase leading up to that visit, including site selection, contracting, IRB approval, and document collection; the SIV is the last step of start-up, not the whole phase.
What is the biggest cause of study start-up delays?
Contract and budget negotiation is commonly the slowest and most variable workstream, because it typically runs through an institution’s legal and finance review chains independently of the clinical and regulatory tracks. IRB resubmissions due to incomplete initial applications are another frequent source of delay.
Who manages study start-up on a clinical trial?
It is cross-functional: a sponsor- or CRO-side CRA/CTA typically coordinates the overall timeline, institutional contracts offices negotiate the trial agreement and budget, the site’s IRB/HRPP office manages ethics review, and site coordinators assemble the regulatory document package.
